Battelle and Zogenix Inc. have renewed their collaborative agreement to co-market Zogenix’s drug delivery system and to apply that technology to biologic therapies requiring high dosage.
Zogenix intends to tap Battelle’s technical resources and technologies for designing self-injection systems and devices that the companies will use to extend DosePro’s dose volumes beyond one milliliter, Zogenix said Tuesday.
William Dunlevy, Battelle vice president and general manager for process and product development, said Zogenix’s DosePro technology is intended to help clients address the demands for self-administered biologic therapies.
The new five-year contract builds on the companies’ previous co-marketing and product testing agreement that began in March 2012, during which Battelle and Zogenix demonstrated a research showing that patients preferred needle-free injection system.
Battelle and Zogenix surveyed 300 rheumatoid arthritis patients for that study.
The companies also presented a research demonstrating DosePro’s capability to deliver AbbVie Inc.’s monoclonal antibody therapeutic called Humira.